

Supplementary Data

SUPPLEMENTARY TABLE S1. ANTIBODIES USED IN THIS STUDY

| <i>Specificity label</i> | <i>Clone</i> | <i>Product no.</i> | <i>Isotype</i> | <i>Source</i> |
|---------------------------------------|--------------|--------------------|----------------|--------------------------|
| Albumin-FITC | Polyclonal | 0220-0204 | | Biogenesis Inc. |
| CD1-FITC | HI149 | 34224x | IgG1 | BD Biosciences |
| CD1a-PE | BL6 | IM1942U | IgG1 | Beckman Coulter |
| CD2-FITC | S5.2 | 347593 | IgG2a | BD Biosciences |
| CD2-PE | T11-RD1 | T11-RD1 | IgG1 | Beckman Coulter |
| CD3-PE | SK7 | 347347 | IgG1 | BD Biosciences |
| CD4-PE | IV T114 | 550630 | IgG1 | BD Biosciences |
| CD5-PE | L17F12 | 347307 | IgG2a | BD Biosciences |
| CD7-PE | 6B7 | MHCD0704 | IgG2a | Invitrogen |
| CD9-PE | M-L13 | 555372 | IgG1 | BD Biosciences |
| CD13-PE | L138 | 347837 | IgG1 | BD Biosciences |
| CD14-PE | TÜK4 | MHCD1404 | IgG2a | Invitrogen |
| CD14 | HCD14 | 325601 | IgG1 | BioLegend |
| CD15-PE | V1MC6 | MHCD1504 | IgM | Invitrogen |
| CD19-PE | SJ25-C1 | MHCD1904 | IgG1 | Invitrogen |
| CD20-PE | HI47 | MHCD2004 | IgG3 | Invitrogen |
| CD24-PE | ML5 | 311105 | IgG2a | BioLegend |
| CD26-PE | BA5b | CD2604 | IgG2a | Invitrogen |
| CD29-PE | MAR4 | 555443 | IgG1 | BD Biosciences |
| CD31-PE | MBC78.2 | MHCD3104 | IgG1 | Invitrogen |
| CD34-PE | 581 | CD34-581 | IgG1 | Invitrogen |
| CD38-PE | HB7 | 347687 | IgG1 | BD Biosciences |
| CD44-PE | MEM85 | MHCD4404 | IgG1 | Invitrogen |
| CD45-FITC | HI30 | MHCD4501 | IgG1 | Invitrogen |
| CD45-PE | HI30 | MHCD4504 | IgG1 | Invitrogen |
| CD49f-PE | GoH3 | 555735 | IgG2a | BD Biosciences |
| CD59-PE | MEM-43 | MHCD5904 | IgG2a | Invitrogen |
| CD56-PE | C5.9 | 0564 | IgG2b | Exalpha Biologicals Inc. |
| CD71-PE | L01.1 | 555537 | IgG2a | BD Biosciences |
| CD90-PE | 5E10 | 555596 | IgG1 | BD Biosciences |
| CD105-PE | SN6 | MHCD10504 | IgG1 | Invitrogen |
| CD117-PE | 104D2 | 340867 | IgG1 | BD Biosciences |
| CD220-PE | 3B6/IR | 559955 | IgG1 | BD Biosciences |
| CD227-FITC | 3H2740 | M4700-05D | IgG3 | US Biological |
| CD235a | 10F7MN | HB-8162 | IgG1 | ATCC |
| CD243-PE | UIC2 | 2370 | IgG2a | Beckmann Coulter |
| CD271-PE | C40-1457 | 557196 | IgG1 | BD Biosciences |
| CD324-PE | 67A4 | 324106 | IgG1 | Biolegend |
| CD326-APC | HEA-125 | 130091254 | IgG1 | Miltenyi Biotech |
| CD326-Alexa Fluor 488 | 9C4 | 324209 | IgG2b | BioLegend |
| CK7/CK8-FITC | CAM-5.2 | 347653 | IgG2a | BD Biosciences |
| CK7-FITC | 2Q1023 | C9097-40D1 | IgG2b | US Biological |
| CK8-FITC | 2Q1026 | C9097-42B1 | IgG1 | US Biological |
| CK19 | RCK108 | M0888 | IgG1 | DAKO |
| SMA-FITC | IA4 | F-3777 | IgG2a | Sigma Chemical Co. |
| Mouse IgG1-FITC | Polyclonal | MG101 | IgG1 | Invitrogen |
| Mouse IgG2a-FITC | Polyclonal | MG2a01 | IgG2a | Invitrogen |
| Mouse IgG1-PE | Polyclonal | MG104 | IgG1 | Invitrogen |
| Mouse IgG2a-PE | Polyclonal | MG2a04 | IgG2a | Invitrogen |
| Mouse IgG2b-PE | Polyclonal | MG2b04 | IgG2b | Invitrogen |
| Mouse IgM-PE | Polyclonal | MGM04 | IgM | Invitrogen |
| Mouse IgG1-APC | Polyclonal | MG105 | IgG1 | Invitrogen |
| Goat anti-mouse IgG1 Alexa Fluor 568 | Polyclonal | A-21124 | | Invitrogen |
| Goat anti-mouse IgG2a Alexa Fluor 568 | Polyclonal | A-21134 | | Invitrogen |
| Goat anti-mouse IgG2b Alexa Fluor 568 | Polyclonal | A-21144 | | Invitrogen |

FITC, fluorescein isothiocyanate; PE, phycoerythrin; APC, allophycocyanin; ATCC, American Type Culture Collection.

SUPPLEMENTARY TABLE S2. QUANTITATIVE POLYMERASE CHAIN REACTION PRIMER SEQUENCES

| Gene | Primers | Position | GenBank accession no. | Product size (bp) | References |
|-------------------|-------------------------------|-----------|-----------------------|-------------------|------------|
| 18S rRNA (F) | 5'- TTCGGAAC TGAGGCCATGAT | 1842–1861 | gi22760900 | 151 | [1] |
| 18S rRNA (R) | 5'- CGAACCTCCGACTTCGTTT | 1992–1973 | | | |
| AAT (F) | 5'- CAGAGGAGGCACCCCTGAA | 1266–1284 | gi28193183 | 71 | [2] |
| AAT (R) | 5'- AGTCCCTTCTCGTCGATGGT | 1336–1316 | | | |
| AFP (F) | 5'- GCAAAGCTGAAAATGCAGTTGA | 622–643 | gi311348 | 129 | [2] |
| AFP (R) | 5'- GGAAAGTTCGGGTCCCAAAA | 750–731 | | | |
| ALB (F) | 5'- TGCTTGAAATGTGCTGATGACAGGG | 861–884 | gi51476389 | 161 | [3] |
| ALB (R) | 5'- AAGGCAAGTCAGCAGGCATCTCATC | 1022–998 | | | |
| CD14 (F) | 5'- AGAGGCTCGGAAGACTTATCG | 331–351 | gi91105163 | 143 | [4] |
| CD14 (R) | 5'- TCGGAGAAGTTGCAGACGC | 473–455 | | | |
| CD31 (F) | 5'- CCTGATGCCGTGGAAAGC | 2374–2391 | gi110347450 | 85 | [4] |
| CD31 (R) | 5'- TCCAGGGATGTGCATCTGG | 2458–2440 | | | |
| CD45 (F) | 5'- AACAGTGGAGAAAGGACGCA | 27–46 | gi34280 | 111 | [5] |
| CD45 (R) | 5'- TGTGTCCAGAAAGGAAAGC | 137–118 | | | |
| CD117 (F) | 5'- GATGACGAGTTGCCCTAGA | 2296–2315 | gi34084 | 233 | [6] |
| CD117 (R) | 5'- CAGGTAGTCGAGCGTTCTC | 2520–2499 | | | |
| CD326 (F) | 5'- CTGGCCGTAAACTGCTTTGT | 278–297 | gi4505058 | 182 | [7] |
| CD326 (R) | 5'- AGCCCATTCAATTGTTCTGGAG | 459–440 | | | |
| CK7 (F) | 5'- CAATGAGACGGAGTTGACAG | 811–830 | gi67782364 | 189 | |
| CK7 (R) | 5'- TGGAGGGTCTCAAACATTGGT | 999–980 | | | |
| CK19 (F) | 5'- CCGCGACTACAGCCACTACT | 404–423 | gi34038 | 152 | [7] |
| CK19 (R) | 5'- GAGCCTGTTCCGCTCTAACAC | 555–536 | | | |
| c-Met (F) | 5'- CTGCCTGCAATCTACAAGGT | 1871–1890 | gi42741654 | 66 | [8] |
| c-Met (R) | 5'- ATGGTCAGCCTTGTCCCTC | 1936–1917 | | | |
| Cyp3A7 (F) | 5'- CCTTACCCCAATTCTGAAGCA | 789–810 | gi13386504 | 198 | [9] |
| Cyp3A7 (R) | 5'- TCCAGATCAGACAGAGCTTGTG | 986–964 | | | |
| HNF3 α (F) | 5'- CATTGCCATCGTGTGCTTGT | 2789–2808 | gi24497500 | 78 | |
| HNF3 α (R) | 5'- CCCGCTGGCTATACTAACACCAT | 2866–2843 | | | |
| Prox1 (F) | 5'- ACATTAGATGGAGAAGTACG | 2165–2188 | gi34147628 | 268 | [10] |
| Prox1 (R) | 5'- CTTCACTATCCA GCTTGCAGA | 2433–2414 | | | |
| TF (F) | 5'- CTACACAGGCCTTCAGGT | 1655–1674 | gi21536430 | 152 | [11] |
| TF (R) | 5'- TACCATCAAGGCACAGCAAC | 1806–1787 | | | |

F, forward; R, reverse.

Supplementary References

- Lie-A-Ling M, CT Bakker, T Deurholt, et al. (2006). Selection of tumour specific promoters for adenoviral gene therapy of cholangiocarcinoma. *J Hepatol* 44:126–133.
- Nava S, M Westgren, M Jaksch, et al. (2005). Characterization of cells in the developing human liver. *Differentiation* 73:249–260.
- Schwartz RE, M Reyes, L Koodie, et al. (2002). Multipotent adult progenitor cells from bone marrow differentiate into functional hepatocyte-like cells. *J Clin Invest* 109:1291–1302.
- Timmermans F, F Van Hauwermeiren, M De Smedt, et al. (2007). Endothelial outgrowth cells are not derived from CD133+ cells or CD45+ hematopoietic precursors. *Arterioscler Thromb Vasc Biol* 27:1572–1579.
- Hussain SZ, SC Strom, MR Kirby, et al. (2005). Side population cells derived from adult human liver generate hepatocyte-like cells *in vitro*. *Dig Dis Sci* 50:1755–1763.
- Hong SH, EJ Gang, JA Jeong, et al. (2005). *In vitro* differentiation of human umbilical cord blood-derived mesenchymal stem cells into hepatocyte-like cells. *Biochem Biophys Res Commun* 330:1153–1161.
- Schmelzer E, E Wauthier and LM Reid. (2006). The phenotypes of pluripotent human hepatic progenitors. *Stem Cells* 24:1852–1858.
- Herrera LJ, T El-Hefnawy, PE Queiroz de Oliveira, et al. (2005). The HGF receptor c-Met is overexpressed in esophageal adenocarcinoma. *Neoplasia* 7:75–84.
- Nishimura M, H Yaguti, H Yoshitsugu, et al. (2003). Tissue distribution of mRNA expression of human cytochrome P450 isoforms assessed by high-sensitivity real-time reverse transcription PCR. *Yakugaku Zasshi* 123:369–375.
- Qin J, DM Gao, QF Jiang, et al. (2004). Prospero-related homeobox (Prox1) is a corepressor of human liver receptor homolog-1 and suppresses the transcription of the cholesterol 7-alpha-hydroxylase gene. *Mol Endocrinol* 18:2424–2439.
- Selden C, SA Chalmers, C Jones, et al. (2003). Epithelial colonies cultured from human explanted liver in subacute hepatic failure exhibit hepatocyte, biliary epithelial, and stem cell phenotypic markers. *Stem Cells* 21:624–631.